Aligos Therapeutics, Inc. (ALGS) Spending and interest coverage
- R&D / revenue · 12 months: Value 2363.02%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 149.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2363.02% | Research and development expense / revenue. Period ending 2026-06-30. $88.38M ÷ $3.74M × 100 ≈ 2363.02% |
| Stock-based compensation / revenue · 12 months | 149.81% | Share-based compensation / revenue. Period ending 2026-06-30. $5.60M ÷ $3.74M × 100 ≈ 149.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 88.38M USD | Research and Development Expense |
| Revenue | 3.74M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.60M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -78.99M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $88.38M | $3.74M | $5.60M | $-78.99M | (m) | 2363.02% | 149.81% | (m) | (m) |
| 2026-03-31 | $78.30M | $4.71M | $5.40M | $-95.67M | (m) | 1664.25% | 114.75% | (m) | (m) |
| 2025-12-31 | $69.45M | $2.19M | $5.04M | $-87.98M | (m) | 3177.17% | 230.74% | (m) | (m) |
| 2025-09-30 | $68.45M | $2.62M | $5.29M | $-86.73M | (m) | 2609.45% | 201.72% | (m) | (m) |
| 2025-06-30 | $61.28M | $3.13M | $5.87M | $-78.50M | (m) | 1956.67% | 187.32% | (m) | (m) |
| 2025-03-31 | $68.41M | $3.23M | $6.76M | $-86.35M | (m) | 2119.11% | 209.51% | (m) | (m) |
| 2024-12-31 | $70.27M | $3.61M | $8.45M | $-89.15M | (m) | 1945.97% | 234.06% | (m) | (m) |
| 2024-09-30 | $76.50M | $3.68M | $9.33M | $-94.59M | (m) | 2080.36% | 253.74% | (m) | (m) |
| 2024-06-30 | $75.59M | $3.51M | $10.50M | $-93.53M | (m) | 2152.28% | 298.86% | (m) | (m) |
| 2024-03-31 | $71.27M | $6.75M | $11.64M | $-86.25M | (m) | 1056.65% | 172.51% | (m) | (m) |
| 2023-12-31 | $73.04M | $6.19M | $12.65M | $-88.13M | (m) | 1179.78% | 204.36% | (m) | (m) |
| 2023-09-30 | $69.88M | $5.52M | $13.48M | $-84.81M | (m) | 1266.23% | 244.34% | (m) | (m) |
| 2023-06-30 | $71.81M | $4.43M | $13.77M | $-84.69M | (m) | 1619.46% | 310.49% | (m) | (m) |
| 2023-03-31 | $71.54M | (m) | $14.57M | $-85.94M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $85.08M | $0.00 | $14.69M | $-97.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $94.58M | (m) | $14.93M | $-112.85M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $104.92M | (m) | $15.04M | $-126.97M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $112.96M | (m) | $14.49M | $-136.14M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $104.15M | $0.00 | $13.46M | $-128.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $103.64M | (m) | $11.11M | $-124.66M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $92.83M | (m) | $8.52M | $-113.15M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $85.46M | (m) | $5.13M | $-104.85M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $79.89M | $0.00 | $2.98M | $-97.83M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $44.04M | (m) | $752.00K | $-54.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |